Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03969992 · ClinicalTrials.gov registry record · Phase 2
A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact
A Phase 2 study, sponsored by Aerogen Pharma Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 261
- Enrollment target
NCT03969992 is a Phase 2 study that has completed, run by Aerogen Pharma Limited. The registered enrollment target is 261 participants.
The verdict
NCT03969992, a Phase 2 study, has completed, sponsored by Aerogen Pharma Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 261 participants
- Enrollment target
Study Summary
The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.
Interventions
- DRUG AeroFact
- OTHER nCPAP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2020-03-04 |
| Est. Completion | 2024-08-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03969992
The ClinicalTrials.gov registry entry for NCT03969992 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerogen Pharma Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AeroFact is the first listed.
NCT03969992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03969992 about?
NCT03969992 is a clinical study titled "A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact". The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.
What is the current status of trial NCT03969992?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 261 participants. The study started on 2020-03-04. Estimated completion is 2024-08-05.
What interventions are being tested in trial NCT03969992?
The interventions under investigation include: AeroFact (DRUG), nCPAP (OTHER).
Who is sponsoring clinical trial NCT03969992?
This trial is sponsored by Aerogen Pharma Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.